The Global Insulin Biosimilars Industry is charting an extraordinary trajectory of growth, with a projected value of US$ 1,507.7 million in 2023, expected to surge beyond US$ 2,096.5 million by 2033. This significant surge is underpinned by a robust adoption rate, positioning insulin biosimilars as a key player alongside other insulin pharmaceutical products. Forecasts indicate …